Near-Adult Height Outcomes in Patients Treated With rhIGF-1 for Severe Growth Failure: Real-World Increlex® Growth Forum Database (IGFD) Registry Data
Authors' conclusion
In a real-world setting, despite patients with SPIGFD initiating rhIGF-1 treatment at a relatively advanced age, rhIGF-1 treatment resulted in improved NAH. The greatest improvements in height outcomes were observed in NPP patients.
Study context
- Population
- Children and adolescents with severe growth failure due to SPIGFD treated with rhIGF-1 (mecasermin) in the Global IGFD Registry who achieved near-adult height (NAH); mean age at rhIGF-1 initiation 11.8 yearsachieved NAH
- Participants
- 102 children
- Exposure
- NPP vs Laron syndrome
- Outcome
- HtSDS gain from rhIGF-1 initiation to NAH
Methodological detailsreal-world, descriptive analyses, linear regression analyses, Data cut-off April 20, 2023
- Real-world
- Descriptive analyses
- Linear regression analyses
- Data cut-off April 20, 2023
Main finding
As reported in the abstract
NPP
1.4
mean · SD 1.0
- Mean (SD) height SD score (HtSDS) gain from rhIGF-1 initiation to NAH, all patients who achieved NAH
- 0.9 (1.1)
- Laron syndrome: reached NAH within the normal range
- 10.5%
Observational data: associations, not effects.
Further findings
- NAH within normal range — Laron syndrome
- 10.5%
- NAH within normal range — Patients with Laron syndrome who were NPP
- 3
NAH within normal range
- Almost half of NPP patients reached NAH within the normal range
Predictors of height gain
- Treatment naivety was predictive of height gain in the overall NAH population
Safety
- Safety data aligned with previous reports
Original publication
Near-Adult Height Outcomes in Patients Treated With rhIGF-1 for Severe Growth Failure: Real-World IGFD Registry Data. J Clin Endocrinol Metab. Published 8 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →